Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Long testimony leaves compounding and med‑spa bill unresolved as committee holds SB 282
Summary
The committee paused action on SB 282 after hours of competing testimony: public‑health advocates urged strict sourcing and certificates of analysis for compounding ingredients; compounding pharmacists and patient advocates warned the bill as written could block access and raise costs for vulnerable patients and pets.
Senate Bill 282, which would set new sourcing and testing rules for bulk drug substances used in compounding products and add oversight for medical spas, prompted the longest and most contentious testimony of the day. Safety advocates described a "Wild West" in which some compounding ingredients arrive from facilities never inspected by the FDA and in some cases contain non‑human‑grade or ineligible substances.
Shabir Imberseftar (Partnership for Safe Medicines) told the committee…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
